---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-039799"
form_type: "8-K"
ticker: "AVBP"
cik: "0001868279"
company_name: "ArriVent BioPharma, Inc."
filed_at: "2025-04-28T23:59:59+00:00"
generated_at: "2026-05-23T05:12:44.046715+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# ArriVent appoints Merdad Parsey to board; Carl Gordon not standing for re-election

## Summary
- Carl L. Gordon not standing for re-election at 2025 annual meeting (June 18); no disagreement with company.
- Board expanded from 7 to 8; Merdad Parsey (former Gilead EVP/CMO) appointed effective April 28, 2025.
- Parsey receives initial option grant of $352,000 and annual cash retainer of $45,000 plus $7,500 for committee service.
- Directors Zhengbin Yao and Kristine Peterson reclassified from Class III to Class I to balance board classes.

## SEC filing metadata
- accession: 0001104659-25-039799
- form_type: 8-K
- ticker: AVBP
- cik: 0001868279
- company_name: ArriVent BioPharma, Inc.
- filed_at: 2025-04-28T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1868279/000110465925039799/0001104659-25-039799-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1868279/000110465925039799/tm2513158d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-039799
- JSON: https://secwatch.observer/filing/0001104659-25-039799.json
- Plain text: https://secwatch.observer/filing/0001104659-25-039799.txt

## Key facts
- Executive change
  Merdad Parsey was appointed as Director at ArriVent BioPharma, Inc..
  - Action: appointed
  - Role: Director
  source text: the Board approved, effective April 28, 2025, an increase in the size of the Board from seven (7) directors to eight (8) directors and appointed Merdad Parsey, M.D., Ph.D. to fill the newly created vacancy on the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1868279/000110465925039799/0001104659-25-039799-index.htm
- Executive change
  Carl L. Gordon departed as Director at ArriVent BioPharma, Inc..
  - Action: not standing for re-election
  - Role: Director
  source text: On April 23, 2025, Carl L. Gordon, Ph.D., CFA notified the board of directors (the “Board”) of ArriVent BioPharma, Inc. (the “Company”) of his decision not to stand for re-election to the Board at the end of his current term at the Company’s 2025 annual meeting of stockholders currently expected to be held on June 18, 2025
  evidence_url: https://www.sec.gov/Archives/edgar/data/1868279/000110465925039799/0001104659-25-039799-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.